Deutsche Bank raised Uniphar Plc (IR:UPR) to “buy” from “hold,” setting a €5 price target.
Analysts note the market undervalues Uniphar’s higher‑growth Medtech and Pharma divisions, which have doubled EBITDA since 2018.
Sum‑of‑the‑parts analysis shows the stock trades at ~9x EV/EBITDA versus a justified ~11.5x, implying upside to €6.
Supply Chain & Retail segment provides resilient cash flow and market leadership in Irish pharma distribution, with efficiency gains from a centre.